![Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations | Journal for ImmunoTherapy of Cancer Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/6/1/8/F1.large.jpg)
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations | Journal for ImmunoTherapy of Cancer
![Frontiers | Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations Frontiers | Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations](https://www.frontiersin.org/files/MyHome%20Article%20Library/330851/330851_Thumb_400.jpg)
Frontiers | Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
![Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer | Nature Reviews Clinical Oncology Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer | Nature Reviews Clinical Oncology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fnrclinonc.2013.208/MediaObjects/41571_2014_Article_BFnrclinonc2013208_Fig2_HTML.jpg)